Introduction
============

Increasing interest in biological studies of pyrazolo\[3,4-*d*\]pyrimidines in the last decade is a consequence of their wide usage as a pharmaceutically important class of compounds \[[@b1-scipharm-2012-80-531]\]. Pyrazolopyrimidine derivatives have considerable potential in the field of chemotherapy, as they were found to exhibit their antitumor activity by inhibiting different types of enzymes such as cyclin-dependent kinase \[[@b2-scipharm-2012-80-531]--[@b4-scipharm-2012-80-531]\], Src and Abl tyrosine kinase \[[@b5-scipharm-2012-80-531]\], glycogen synthase kinase-3 \[[@b6-scipharm-2012-80-531]--[@b8-scipharm-2012-80-531]\], adenosine deaminase \[[@b9-scipharm-2012-80-531]\], and epidermal growth factor receptor protein tyrosine kinase \[[@b10-scipharm-2012-80-531]\]. The derivatives of pyrazolo\[3,4-*d*\]pyrimidine have already been discovered as antitumor agents by the NCI (National Cancer Institute, USA) on HCT116 and other cell lines. The potency of these compounds is enhanced in anilide derivatives, and this translates into tumor growth inhibition in a mouse xenograft model \[[@b2-scipharm-2012-80-531]\]. Some pyrazolo\[3,4-*d*\]pyrimidines (**1**, [Figure 1](#f1-scipharm-2012-80-531){ref-type="fig"}) structurally related with allopurinol, have also been reported as potent inhibitors of xanthine oxidase and the growth of several human tumor cell lines \[[@b11-scipharm-2012-80-531]\]. In addition, several substituted pyrazolo\[3,4-*d*\]pyrimidines (**2**) were reported as potent antitumor agents \[[@b12-scipharm-2012-80-531]\].

Both the above findings and 4-substituted-1*H*-pyrazolo\[3,4-*d*\]-pyrimidines were reported to be cytotoxic and antitumor agents \[[@b1-scipharm-2012-80-531], [@b13-scipharm-2012-80-531]--[@b15-scipharm-2012-80-531]\]. In order to explore this possibility, compounds were prepared that had diverse groups at position 4 of the pyrazolopyrimidine core, and their antitumor activity was tested.

Results and Discussion
======================

Chemistry
---------

The synthesis of the designed compounds is outlined in [schemes 1](#f3-scipharm-2012-80-531){ref-type="fig"}, [2](#f4-scipharm-2012-80-531){ref-type="fig"}, and [3](#f5-scipharm-2012-80-531){ref-type="fig"}. The main precursors for the synthesis of target derivatives, i.e. **Ia,b** and **IIa--c**, were prepared by a previously published synthetic method presented in [Scheme 1](#f3-scipharm-2012-80-531){ref-type="fig"}. Compounds **IIIa,b** were prepared according to the synthetic methods presented in [Scheme 2](#f4-scipharm-2012-80-531){ref-type="fig"}, either by heating compounds **Ia,b** in formamide or by heating compounds **IIa,b** in formic acid. Both procedures had high yields, but the second one had an even higher yield. Compound **IIIc** was prepared only by using one synthetic method from derivative **IIc** in formic acid, as it had the better yield. Structures of newly prepared compounds were confirmed by ^1^H NMR, IR, mass spectroscopy, and microanalyses.

On the other hand, synthesis of **IVa--c** presented in [scheme 2](#f4-scipharm-2012-80-531){ref-type="fig"} was performed by the reflux of **IIIa--c** in phosphorus oxychloride. The structures of the new compounds were confirmed by ^1^H NMR, which revealed disappearance of the singlet D~2~O exchangeable signal corresponding to NH, and showed an increased deshielding of H at position 6, due to the inductive effect of the chlorine atom. It was also confirmed by mass spectra which gave fragments showing the isotopic pattern of the chlorine atom.

The synthesis of **Va--g** and **VIIa--c** was outlined in [scheme 3](#f5-scipharm-2012-80-531){ref-type="fig"}. First, **Va--g** were obtained by the reflux of **IVa--c** with the appropriate amine using triethylamine as a catalyst, and the formed derivatives were confirmed by ^1^H NMR, which revealed appearance of the singlet D~2~O exchangeable signal corresponding to NH, and appearance of other signals characterizing the introduced groups. The structures of some of these derivatives were additionally confirmed by mass spectra. ^13^C NMR was performed on compounds **Va**, **Vc**, and **VIIa. Va** showed distinct aromatic carbons where the carbon at position 3 of the pyrazole ring appeared at 101.76, while that of the pyrimidine ring at position 6 was the highest desheilded and appeared at 156.35ppm. On the other hand, the aromatic ring at position 1 of the pyrazole ring gives aromatic carbons, which are given the numbers 1′,2′,3′,4′,5′, and 6′, and that attached to the amine at the pyrimidine ring gives aromatic carbons marked as 1″, 2″, 3″, 4″, 5″ and 6″. **Vc** showed two distinct doublet signals belonging to the two CH~2~ groups attached to the NH group. The presence of the ethylene spacer was further confirmed by DEPT technique.

Second, **VIIa-c** were synthesized by the reflux of **IVc** with hydrazine, producing **VI** which was confirmed by ^1^H NMR, IR spectrum, microanalysis, and mass spectrum in which appearance of a singlet proton at δ 8.36 ppm in ^1^H NMR indicated slight shielding of the proton at position 6 of the pyrimidine ring, due to the removal of the chlorine atom, and a broad range of the D~2~O exchangeable signal of NH and NH~2~ groups at 3.82 and 4.95 ppm, and by the mass spectrum which shows M^+^, M^+^ + 2 at m/z 274, 276 as 100.00%, 49.15%.

Furthermore, **VI** was condensed with appropriate aldehydes producing **VIIa--c,** the structure of which was confirmed by ^1^H NMR, ^13^C NMR, IR spectra, microanalyses, and mass spectra. The IR spectrum shows the disappearance of the IR peak equivalent to NH~2~. In ^1^H NMR, the appearance of the D~2~O exchangeable broad singlet indicated the presence of NH, deshielded singlet of N=CH, in addition to different peaks equivalent to different substituents in each derivative. The OH group of compound **VIIa** appeared in the IR at 3369 cm^−1^ as an exchangeable peak in ^1^H NMR at10.20ppm. The OCH~3~ group of compound **VIIb** was detected by ^1^H NMR appearing more deshielded at 3.82 ppm than the CH~3~ group at position 3 at 2.79 ppm. Compound **VIIc** mainly showed the NO~2~ group in the IR at 1437, 1346 and the aromatic protons of the benzene ring 2″, 4″, 5″, and 6″ with a deshielded singlet signal equivalent to 2″ at 8.7--8.8, proving the m-substitution.

Antitumor activity
------------------

The antitumor activity was determined for the newly synthesized compounds at the NCI for *in vitro* one-dose testing and detection of IC50 of their antitumor activity on 60 different cell lines. Compound **Vc**, **Vg**, **VIIa**, and **VIIc** were found to have the highest inhibitory activity on many cell lines. The obtained results of the tested derivatives showed a distinctive potential pattern of selectivity, as well as broad-spectrum antitumor activity ([Table 1](#t1-scipharm-2012-80-531){ref-type="table"}). Compound **VIIa** was subjected to 5-dose testing, as it showed the highest activity among other derivatives showing inhibition of 57 different cell lines ([Table 2](#t2-scipharm-2012-80-531){ref-type="table"}).

Experimental
============

Chemistry
---------

All melting points were determined on the Stuart apparatus and the values given are uncorrected. The IR spectra were determined on the Shimadzu IR 435 spectrophotometer (KBr, cm^−1^), Faculty of Pharmacy, Cairo University, Egypt. The ^1^H NMR and ^13^C NMR spectra were recorded on the Varian Gemini 75 MHz spectrophotometer using TMS as the internal standard. Chemical shift values are recorded in ppm on the δ scale, Microanalysis Center, Cairo University, Egypt. Mass spectra were recorded on a Hewlett Packard 5988 spectrometer, Microanalysis Center, Cairo University, Egypt. Elemental analyses were carried out at the Microanalysis Center, Cairo University, Egypt; the values found were within ±0.35% of the theoretical ones. Progress of the reactions was monitored using TLC sheets precoated with the UV fluorescent silica gel, Merck 60F 254, and were visualized using a UV lamp.

The synthesis of the target compounds is outlined in [Schemes 1](#f3-scipharm-2012-80-531){ref-type="fig"}--[3](#f5-scipharm-2012-80-531){ref-type="fig"}. Compounds **Ia** \[[@b16-scipharm-2012-80-531]\], **Ib** \[[@b17-scipharm-2012-80-531]\], **IIa--c** \[[@b18-scipharm-2012-80-531]--[@b20-scipharm-2012-80-531]\], **IIIa** \[[@b21-scipharm-2012-80-531]\], and **Iva** \[[@b22-scipharm-2012-80-531]\] were prepared as reported in the literature.

Procedures for the synthesis of compounds IIIb and IIIc
-------------------------------------------------------

### Method 1

A suspension of the appropriate derivative **Ia,b** (0.01 mol) in formamide (30 ml) was stirred at 145°C for 3 h; the solution was then cooled by being poured on ice-cold water, filtered, washed with water, dried, and finally crystallized from formic acid.

### Method 2

A suspension of the appropriate derivative **IIa--c** (0.01 mol) in 85% formic acid (40 ml), was heated under reflux for 7 h; the reaction mixture was then cooled, filtered, washed with water, dried, and crystallized from formic acid.

### 3-Methyl-1-(4-nitrophenyl)-1,5-dihydro-4H-pyrazolo\[3,4-d\]pyrimidin-4-one (**IIIb**)

Yield: 2.6 g (96% by method 2); M.p.: \>300°C; ^1^H NMR (300 MHz, DMSO-d~6~): δ = 3.15 (s, 3H, CH~3~); 8.20 (s, 1H, C6-H); 8.34 (d, *J =* 9.3 Hz, 2H, ArH C2',6'); 8.39 (d, *J =* 9.6 Hz, 2H, ArH C3',5'); 12.51 (s, 1H, NH, D~2~O exchangeable) ppm; IR (cm^−1^): 3370(NH), 3075, 3034 (CH aromatic), 2911 (CH aliphatic),1686 (C=O), 1589 (C=N),1441,1337(NO~2~); MS (70 ev): *m/z* 271 (M^+^, 100%). Anal. Calcd for C~12~H~9~ N~5~O~3~ (271.23): C, 53.14; H, 3.34; N, 25.82. Found: C, 53.30; H, 3.64; N, 26.36

### 1-(4-Chlorophenyl)-3-methyl-1,5-dihydro-4H-pyrazolo\[3,4-d\]pyrimidin-4-one (**IIIc**)

Yield: 1.94 g (74% by method 2); M.p.: \>300°C; ^1^H NMR (300 MHz, DMSO-d~6~): *δ* = 3.30 (s, 3H, CH~3~); 7.60 (d, *J =* 9.0 Hz, 2H, ArH C3',5'); 8.08 (d, 2H, *J =* 9.0 Hz, ArH C2',6'); 8.15 (s, 1H, C6-H); 12.37 (s, 1H, NH, D2O exchangeable) ppm; IR (cm^−1^): 3422 (NH), 3121, 3040 (CH aromatic) 2974 (CH aliphatic),1670 (C=O), 1589 (C=N); MS (70 ev): *m/z* 261 (M^+^ + 1, 9.24%). Anal. Calcd for C~12~H~9~ClN~4~O (260.68): C, 55.29; H, 3.48; N, 21.49. Found: C, 55.36; H, 3.69; N, 21.41.

General procedure for the synthesis of compounds IVb and IVc
------------------------------------------------------------

A suspension of the appropriate derivative **IIIa--c** (0.01 mol) in phosphorus oxychloride (80 ml) was heated under reflux for 3 h; the solution was cooled and then poured onto ice-cold water. The precipitated product was filtered, dried, and crystallized from ethanol.

### 4-Chloro-3-methyl-1-(4-nitrophenyl)-1H-pyrazolo\[3,4-d\]pyrimidine (**IVb**)

Yield: 2.03 g (70%), M.p.: 210--212°C; ^1^H NMR (200 MHz, DMSO-d~6~): *δ* = 2.71 (s, 3H, CH~3~); 8.37 (d, *J =* 9.4 Hz, 2H, ArH C2',6'); 8.41 (d, *J =* 9.4 Hz, 2H, ArH C3',5'); 8.96 (s, 1H, C6-H) ppm; IR (cm^−1^): 3120, 3080 (CH aromatic), 2905 (CH aliphatic), 1597,1576 (C=N), 1445, 1341 (NO~2~); MS (70 ev): *m/z* 289 (M^+^, 100%). Anal. Calcd for C~12~H~8~ClN~5~O~2~ (289.68): C, 49.75; H, 2.78; N, 24.18. Found: C, 49.60; H, 2.90; N, 24.22.

### 4-Chloro-1-(4-chlorophenyl)-3-methyl-1H-pyrazolo\[3,4-d\]pyrimidine (**IVc**)

Yield: 1.48 g (53%), M.p.: 189--190°C; ^1^H NMR (300 MHz, DMSO-d~6~): *δ* = 3.40 (s, 3H, CH~3~); 7.65 (d, *J =* 9.0 Hz, 2H, ArH C3',5'); 8.16 (d, 2H, *J =* 9.0 Hz, ArH C2',6'); 8.92 (s, 1H, C6-H) ppm; IR (cm^−1^): 3095, 3065 (CH aromatic), 2924 (CH aliphatic), 1589,1574 (C= N); MS (70 ev): *m/z* 278 (M^+^, 87.22). Anal. Calcd for C~12~H~8~Cl~2~N~4~ (279.12): C, 51.64; H, 2.89; N, 20.07. Found: C, 51.43; H, 3.01; N, 19.81.

General procedure for the synthesis of compounds Va--g
------------------------------------------------------

A suspension of the appropriate derivative **IVa--c** (0.01 mol) and the appropriate amine (0.01 mol) in ethanol (30 ml), triethylamine (0.3 g, 0.03 mol), was added and the reaction mixture was heated under reflux for 2--7 h; (the reaction was monitored using TLC until the starting materials were consumed in the reaction). The reaction mixture was allowed to cool leading to separation of the product, and then the crude product was filtered, dried, and crystallized from the appropriate solvent.

### 3-Methyl-N,1-diphenyl-1H-pyrazolo\[3,4-d\]pyrimidin-4-amine (**Va**)

Yield: 0.15 g (49%), M.p.: 144--145°C (ethanol/water); ^1^H NMR (200 MHz, CDCl~3~): *δ* = 2.88 (s, 3H, CH~3~); 7.00 (s, 1H, NH); 7.20--7.35 (m, 3H, ArH C3",4",5"); 7.40--7.55 (m, 3H, ArH C3',4',5'); 7.72 (d, *J =* 9.0 Hz, 2H, ArH C2",6"); 8.20 (d, *J =* 9.0 Hz, 2H, ArH C2',6'); 8.55 (s, 1H, C6-H) ppm.; ^13^C NMR (75 MHz, CDCl~3~): *δ* = 15.17 (q, 1C, CH~3~); 101.76 (s, 1C, C 3a); 121.48 (d, 2C, ArC 2",6"); 121.82 (d, 2C, ArC 2',6'); 124.84 (d, 1C, ArC 4"); 126.38 (d, 1C, ArC 4'); 129.15 (d, 2C, ArC 3',5'); 129.22 (d, 2C, ArC 3",5"); 137.73 (s, 1C, ArC 1'); 138.73 (s, 1C, ArC 1"); 140.73 (s, 1C, C 3); 154.30 (s, 1C, C 7a); 155.60 (s, 1C, C 4); 156.35 (d, 1C, C 6) ppm; IR (cm^−1^): 3455 (NH), 3080, 3020 (CH aromatic), 2930 (CH aliphatic); MS (70 ev): *m/z* 301 (M^+^, 78.78%). Anal. Calcd for C~18~H~15~N~5~ (301.35): C, 71.74; H, 5.02; N, 23.24. Found: C, 72.00; H, 4.97; N, 23.07.

### N-(4-Methoxyphenyl)-3-methyl-1-phenyl-1H-pyrazolo\[3,4-d\]pyrimidin-4-amine (**Vb**)

Yield: 0.20 g (59%), M.p.: 121--122°C (ethanol/water); ^1^H NMR (200 MHz, DMSO-d~6~): *δ* = 2.77 (s, 3H, CH~3~); 3.80 (s, 3H, OCH~3~); 6.99 (d, *J =* 6.6 Hz, 2H, ArH C3",5"); 7.32 (t, *J =* 6.6 Hz, 1H, ArH C4'); 7.55 (d, *J =* 6.0 Hz & m, 4H, ArH C2",6",3',5'); 8.20 (d, *J =* 8.2 Hz, 2H, ArH C2',6'); 8.38 (s, 1H, C6-H); 8.76 (s, 1H, NH, D2O exchangeable) ppm; IR (cm^−1^): 3439 (NH), 3080, 3028 (CH aromatic), 2976 (CH aliphatic). Anal. Calcd for C~19~H~17~N~5~O (331.37): C, 68.87; H, 5.17; N, 21.13. Found: C, 68.90; H, 5.00; N, 21.01

### 3-Methyl-1-phenyl-N-(2-phenylethyl)-1H-pyrazolo\[3,4-d\]pyrimidin-4-amine (**Vc**)

Yield: 0.10 g (30%), M.p.: 151--152°C (ethanol/water); ^1^H NMR (200 MHz, CDCl~3~): *δ* = 2.45 (s, 3H, CH~3~); 3.05 (t, *J =* 9.0 Hz, 2H, CH~2~); 3.88 (t, *J =* 9.0 Hz, 2H, CH~2~); 5.20 (s, 1H, NH); 7.25--7.40 (m, 5H, ArH"); 7.45--7.55 (m, 3H, ArH C3',4',5'); 8.18 (d, *J =* 9.0 Hz, 2H, ArH C2',6'); 8.47 (s, 1H, C6-H) ppm; ^13^C NMR (75 MHz, CDCl~3~): *δ* = 14.73 (q, 1C, CH~3~); 35.33 (t, 1C, CH~2~); 41.70 (t, 1C, CH~2~); 101.33 (s, 1C, ArC C 3a); 121.38 (d, 2C, ArC C 2',6'); 126.14 (d, 2C,ArC C4', C4"); 126.89 (d, 2C, ArC C2",6"); 128.89 (d, 2C, ArC C3",5"); 129.08 (d, 2C, ArC C3',5'); 138.56 (s,1C, ArC C 1"); 138.89 (s, 1C, ArC C 1'); 141.17 (s, 1C, ArC C 3); 153.99 (s, 1C, ArC C7a); 156.66 (s, 1C, ArC C6); 157.53 (s, 1C, ArC C4) ppm; IR (cm^−1^): 3428 (NH), 3030 (CH aromatic), 2940, 2922 (CH aliphatic). MS (70 ev): *m/z* 329 (M^+^, 16.33%). Anal. Calcd for C~20~H~19~N~5~ (329.40): C, 72.93; H, 5.81; N, 21.26. Found: C, 72.73; H, 5.90; N, 21.11.

### 3-Methyl-1-(4-nitrophenyl)-N-phenyl-1H-pyrazolo\[3,4-d\]pyrimidin-4-amine (**Vd**)

Yield: 0.28 g (80%), M.p.: 259--260°C (benzene); ^1^H NMR (300 MHz, DMSO-d~6~): *δ* = 2.78 (s, 3H, CH~3~); 7.20 (t, *J =* 7.2 Hz, 1H, ArH C4"); 7.40 (t, *J =* 7.8 Hz, 2H, ArH C3",5"); 7.68 (d, *J =* 6.6 Hz, 2H, ArH C2",6"); 8.40 (d, *J =* 7.2 Hz, 2H, ArH C2',6'); 8.49 (s, 1H, C6-H); 8.58 (d, *J =* 7.2 Hz, 2H, ArH C3',5'); 8.88 (s, 1H, NH, D2O exchangeable) ppm; IR (cm^−1^): 3431 (NH), 3040 (CH aromatic), 2900 (CH aliphatic), 1443, 1344 (NO~2~). Anal. Calcd for C~18~H~14~N~6~O~2~ (346.34): C, 62.42; H, 4.07; N, 24.27. Found: C, 62.59; H, 3.99; N, 24.57.

### 3-Methyl-1-(4-nitrophenyl)-N-(2-phenylethyl)-1H-pyrazolo\[3,4-d\]pyrimidin-4-amine (**Ve**)

Yield: 0.13 g (36%), M.p.: 214°C (benzene); ^1^H NMR (200 MHz, DMSO-d~6~): *δ* = 2.63 (s, 3H, CH~3~); 2.96 (t, *J =* 7.0 Hz, 2H, CH~2~); 3.80 (t, *J =* 7.0 Hz, 2H, CH~2~); 7.20--7.39 (m, 5H, ArH"); 7.53 (s, 1H, NH, D2O exchangeable); 8.39 (d, *J =* 9.4 Hz, 2H, ArH C3',5'); 8.45 (s, 1H, C6-H); 8.57 (d, *J =* 9.4 Hz, 2H, ArH C2',6') ppm; IR (cm^−1^): 3439 (NH), 3080, 30210 (CH aromatic), 2940, 2920 (CH aliphatic), 1441, 1346 (NO~2~).; MS (70 ev): *m/z* 374 (M^+^, 13.47%). Anal. Calcd for C~20~H~18~N~6~O~2~ (374.4): C, 64.16; H, 4.85; N, 22.45. Found: C, 64.27; H, 4.89; N, 22.66.

### 1-(4-Chlorophenyl)-N-(4-methoxyphenyl)-3-methyl-1H-pyrazolo\[3,4-d\]pyrimidin-4-amine (**Vf**)

Yield: 0.26 g (70%), M.p.: 198--200°C (ethanol); ^1^H NMR (300 MHz, DMSO-d~6~): *δ* = 2.74 (s, 3H, CH~3~); 3.78 (s, 3H, OCH~3~); 6.97 (d, *J =* 7.2 Hz, 2H, ArH C3",5"); 7.53 (d, *J =* 7.0 Hz, 2H, ArH C2",6"); 7.58 (d, *J =* 6.6 Hz, 2H, ArH C3',5'); 8.25 (d, *J =* 6.9 Hz, 2H, ArH C2',6'); 8.36 (s, 1H, C6-H); 8.74 (s, 1H, NH, D~2~O exchangeable) ppm; IR (cm^−1^): 3443 (NH), 3010 (CH aromatic), 2934, 2915 (CH aliphatic); MS (70 ev): *m/z* 365 (M^+^, 24.61%). Anal. Calcd for C~19~H~16~ClN~5~O (365.82): C, 62.38; H, 4.41; N, 19.14. Found: C, 65.59; H, 4.43; N, 18.95.

### 1-(4-Chlorophenyl)-3-methyl-N-(2-phenylethyl)-1H-pyrazolo\[3,4-d\]pyrimidin-4-amine (**Vg**)

Yield: 0.24 g (65%), M.p.: 123--125°C (ethanol/water); ^1^H NMR (300 MHz, DMSO-d~6~): *δ* = 2.61 (s, 3H, CH~3~); 2.95 (t, *J =* 7.8 Hz, 2H, CH~2~); 3.76 (t, *J =* 7.5 Hz, 2H, CH~2~); 7.21--7.34 (m, 5H, ArH"); 7.34 (s, 1H, NH, D~2~O exchangeable); 7.56 (d, *J =* 9.0 Hz, 2H, ArH C3',5'); 8.24 (d, *J =* 9.0 Hz, 2H, ArH C2',6'); 8.39 (s, 1H, C6-H) ppm; IR (cm^−1^): 3418 (NH), 3100, 3026 (CH aromatic), 2924, 2860 (CH aliphatic). Anal. Calcd for C~20~H~18~ClN~5~ (363.84): C, 66.02; H, 4.99; N, 19.25. Found: C, 66.13; H, 5.15; N, 19.19.

Synthesis of 1-(4-chlorophenyl)-4-hydrazino-3-methyl-1H-pyrazolo\[3,4-d\]pyrimidine (VI)
----------------------------------------------------------------------------------------

Hydrazine hydrate (0.1 mol) was added to a suspension of **IVc** (0.01 mol) in ethanol (35 ml), the reaction mixture was heated under reflux for 2.5 h; the precipitated product was filtered, washed with ethanol, dried, and crystallized from ethanol.

Yield: 2.55 g (93%), M.p.: 244--246°C; ^1^H NMR (300 MHz, DMSO-d~6~): *δ* = 2.62 (s, 3H, CH~3~); 3.82 (s, 1H, NH, D~2~O exchangeable); 4.95 (broad s, 2H, NH~2~, D~2~O exchangeable); 7.56 (d, *J* = 9.0 Hz, 2H, H3',5'); 8.22 (d, *J* = 9.0 Hz, 2H, H2',6'); 8.36 (s, 1H, H6) ppm; IR (cm^−1^): 3294 (NH), 3278 & 3199 (NH~2~); MS (70 ev): *m/z* 276 (M^+^ + 2); 274 (100%) (M^+^). Anal. Calcd for C~12~H~11~ClN~6~ (274.71): C, 52.47; H, 4.04; N, 30.59. Found: C, 52.67; H, 4.24; N, 30.59.

General procedure for the synthesis of compounds VIIa--c
--------------------------------------------------------

A suspension of **VI** (1 mmol), and the appropriate aldehyde (1 mmol) in ethanol (35 ml), was heated under reflux with stirring for 3--4 h; the reaction mixture was then cooled and the separated precipitate was filtered, dried, and crystallized from ethanol.

### 2-({2-\[1-(4-Chlorophenyl)-3-methyl-1H-pyrazolo\[3,4-d\]pyrimidin-4-yl\]hydrazinylidene}-methyl)phenol (**VIIa**)

Yield: 0.24 g (63%), M.p.: 269--270°C; ^1^H NMR (300 MHz, DMSO-d~6~): *δ* = 2.76 (s, 3H, CH~3~); 6.88--6.95 (m, 1H, H5"); 7.28--7.33 (m, 1H, H3"); 7.39--7.43 (m, 1H, H4"); 7.58--7.63 (m, 1H, H6"); 7.80 (d, *J* = 9.0 Hz, 2H, H3',5'); 8.04 (d, *J* = 9.0 Hz, 2H, H2',6'); 8.23 (s, 1H, HC=N); 8.60 (s, 1H, H6); 10.20 (broad s, 1H, OH, D~2~O exchangeable); 11.90 (broad s, 1H, NH, D~2~O exchangeable) ppm; ^13^C NMR (75 MHz, DMSO-d~6~): *δ* = 14.10 (q, 1C, CH~3~); 102.00 (s, 1C, ArC C3a); 117.80 (s,1C, ArC C 3"); 119.80 (d, 2C, ArC C2',6'); 125.38 (s,1C, ArC C5"); 127.80 (s,1C, ArC C6"); 129.00 (d,2C, ArC C3',5'); 131.50 (s,1C, ArC C4'); 132.90 (s,1C, ArC C 4"); 136.54 (s, 1C, ArC C 1"); 138.26 (s,1C, ArC C 1'); 144.93 (s, 1C,C=N); 147.85 (s, 1C, ArC C3); 149.50 (s, 1C, ArC C7a); 153.57 (s, 1C, ArC C6); 157.47 (s, 1C, ArC C2"); 157.71 (s, 1C, ArC C4) ppm; IR (cm^−1^): 3433 (NH), 3369 (OH); MS (70 ev): *m/z* 380 (M^+^ + 2); 378 (M^+^); 243 (100%). Anal. Calcd for C~19~H~15~ClN~6~O (378.82): C, 60.24; H, 3.99; N, 22.19. Found: C, 60.50; H, 3.89; N, 22.44.

### 1-(4-Chlorophenyl)-4-\[2-(4-methoxybenzylidene)hydrazinyl\]-3-methyl-1H- pyrazolo\[3,4-d\]pyrimidine (**VIIb**)

Yield: 0.32 g (82%), M.p.: 247--248°C; ^1^H NMR (300 MHz, DMSO-d~6~): *δ* = 2.79 (s, 3H, CH~3~); 3.82 (s, 3H, OCH~3~); 7.00 (d, *J* = 8.7 Hz, 2H, H3",5"); 7.60 (d, *J* = 9.0 Hz, 2H, H3',5'); 7.65 (d, *J* = 8.7 Hz, 2H, H2",6"); 7.95 (d, *J* = 9.0 Hz, 2H, H2',6'); 8.20 (s, 1H, HC=N); 8.35 (s, 1H, H6); 11.87 (broad s, 1H, NH, D~2~O exchangeable) ppm; IR (cm^−1^): 3220 (NH); MS (70 ev): *m/z* 393 (M^+^ + 1); 392 (100%). Anal. Calcd for C~20~H~17~ClN~6~O (392.84): C, 61.15; H, 4.36; N, 21.39. Found: C, 61.39; H, 4.51; N, 21.10.

### 1-(4-Chlorophenyl)-3-methyl-4-\[2-(2-nitrobenzylidene)hydrazinyl\]-1H- pyrazolo\[3,4-d\]pyrimidine (**VIIc**)

Yield: 0.35 g (86%), M.p.: 286--288°C; ^1^H NMR (300 MHz, DMSO-d~6~): *δ* = 2.77 (s, 3H, CH~3~); 7.56 (d, *J* = 9.0 Hz, 2H, H3',5'); 7.78--7.84 (m, 2H, H5",6"); 8.07 (d, *J* = 9.0 Hz, 2H, H2',6'); 8.08--8.13 (m, 1H, H4"); 8.33 (s, 1H, HC=N); 8.53 (s, 1H, H6); 8.75--8.80 (m, 1H, H2"); 12.12 (broad s, 1H, NH, D~2~O exchangeable) ppm; IR (cm^−1^): 3327 (NH), 1437, 1346 (NO~2~). Anal. Calcd for C~19~H~14~ClN~7~O~2~ (407.81): C, 55.96; H, 3.46; N, 24.04. Found: C, 56.20; H, 3.56; N, 23.96.

Antitumor activity
------------------

The compounds were prepared in DMSO: glycerol 9:1 at a concentration of 4 mM for the single-dose assay. The solution was diluted 1:400, giving a test concentration of 10 μM. The human tumor cell lines of the cancer screening panel were prepared according to the standard procedure of the American National Cancer Institute (NCI), and the tests were performed at the American National Cancer Institute (NCI) \[[@b23-scipharm-2012-80-531], [@b24-scipharm-2012-80-531]\].

Compound **VIIa**, which was subjected to a 5-dose assay, was prepared at a concentration 40 mM. The solution was diluted 1:400, giving a Test concentration of 100 μM.

The human tumor cell lines of the cancer screening panel were prepared according to the standard procedures of the NCI. The results are summarized in [Tables 1](#t1-scipharm-2012-80-531){ref-type="table"} and [2](#t2-scipharm-2012-80-531){ref-type="table"}, and [Figure 2](#f2-scipharm-2012-80-531){ref-type="fig"}.

Conclusion
==========

The objective of this study was to synthesize and investigate the anticancer inhibition activity of selected pyrazolopyrimidines with the hope of discovering new structure leads to serve as potential anticancer agents. The newly synthesized compounds showed good inhibitory activity on different cell lines at a concentration of 10μM, making them leading chemical entities for further modification to render them as clinically useful therapeutic agents. Compound **Vc** showed 65.57% and 53.25% on the k-562 and molt-4 cell lines of leukemia. **Vg** produced 76.32 and 51.72 percentage inhibition on the K-562 and HOP-92 cell lines of leukemia and small lung cancer, **VIIc** showed 90% inhibition on the ovcar-3 cell line of ovarian cancer, and 82% and 84% inhibition on the k-562 and molt-4 cell lines of leukemia. The highest activity was presented by compound **VIIa**, which showed good inhibitory activity against 57 cell lines, and was the reason for performing 5-dose testing on this compound and measuring its GI50 (growth inhibition)and LC50 (lethal concentration), which further revealed its high potency against most of the cell lines.

We would like to thank the American National Cancer Institute (NCI) team for their help in carrying out the antitumor screening of the newly synthesized compounds.
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###### 

Inhibition percent of the tested compounds (10^−5^ Molar) on different 60 cell lines

  Cell line type               Tested compounds and inhibition percent of cell lines                                                                                                       
  ---------------------------- ------------------------------------------------------- ------- ----------- ----------- ----------- ------- ----------- ----------- ----------- ----------- -----------
  Leukemia                     CCRF-CEM                                                19.43   4.00        6.94        2.25        --      2.45        0.33        **93.59**   --          **79.59**
  HL-60(TB)                    29.20                                                   11.40   22.22       8.87        35.22       --      29.98       **73.60**   --          **69.05**   
  K-562                        30.71                                                   24.64   **65.57**   5.24        23.27       --      **76.32**   **81.45**   19.22       **82.62**   
  MOLT-4                       30.65                                                   32.39   **53.25**   21.34       35.41       12.37   43.41       **90.57**   20.53       **84.60**   
  RPMI-8226                    23.57                                                   9.63    12.33       16.39       3.17        19.90   17.27       **62.86**   6.07        33.66       
  SR                           36.93                                                   41.72   **53.71**   28.86       37.77       20.94   34.91       **95.20**   18.44       **48.73**   
                                                                                                                                                                                           
  Non-Small Cell Lung Cancer   A549/ATCC                                               --      4.05        6.18        10.26       0.26    3.61        --          **90.54**   --          --
  EKVX                         --                                                      5.68    8.75        --          **47.45**   13.84   19.40       **61.94**   --          15.99       
  HOP-62                       --                                                      2.91    9.60        --          --          19.97   7.30        **92.07**   --          --          
  HOP-92                       34.14                                                   8.10    11.46       6.51        8.78        28.98   **51.17**   **55.93**   12.52       **79.55**   
  NCI-H226                     --                                                      --      --          --          2.27        10.33   3.81        **47.25**   --          --          
  NCI-H23                      --                                                      --      --          --          4.22        10.44   4.32        **63.00**   --          5.70        
  NCI-H322M                    --                                                      --      --          --          --          \_      --          **66.66**   --          3.60        
  NCI-H460                     --                                                      --      --          10.24       8.52        4.20    3.49        **94.96**   --          22.17       
  NCI-H 522                    8.39                                                    9.21    17.72       19.25       --          28.80   4.48        \_          --          --          
                                                                                                                                                                                           
  Colon Cancer                 COLO 205                                                4.67    --          --          --          --      8.75        6.22        **81.33**   --          4.75
  HCC-2998                     --                                                      --      --          --          --          --      \_          **68.95**   --          5.17        
  HCT-116                      --                                                      0.89    6.87        **33.53**   7.57        8.26    5.93        **73.26**   --          --          
  HCT-15                       3.74                                                    9.57    7.60        --          4.73        6.88    6.10        **68.08**   --          --          
  HT29                         12.25                                                   18.87   5.24        10.25       --          14.96   4.20        **79.92**   0.97        9.36        
  KM12                         --                                                      --      --          --          4.92        5.48    --          **71.56**   --          33.45       
  SW-620                       0.79                                                    --      --          --          0.72        2.59    --          **64.89**   --          11.24       
                                                                                                                                                                                           
  CNS Cancer                   SF-268                                                  5.96    --          --          3.91        6.41    --          --          **90.33**   --          **41.99**
  SF-295                       --                                                      --      2.42        --          --          --      --          **75.51**   --          --          
  SF-539                       3.88                                                    0.50    --          1.85        0.58        9.76    --          **85.97**   --          --          
  SNB-19                       --                                                      --      --          2.95        2.93        1.78    --          **70.42**   --          3.66        
  SNB-75                       0.60                                                    10.60   --          --          12,15       10.17   --          **36.41**   0.88        0.87        
  U251                         --                                                      --      --          0.50        --          --      --          **86.92**   0.73        17.78       
                                                                                                                                                                                           
  Melanoma                     LOX IMVI                                                --      1.66        7.32        15.16       --      19.19       --          **64.88**   0.69        6.68
  MALME-3M                     --                                                      --      --          --          --          \_      --          **51.30**   --          2.87        
  MDAMB435                     --                                                      --      6.98        --          5.22        --      --          **72.73**   --          2.94        
  SK-MEL-2                     --                                                      --      --          --          --          10.73   5.94        **87.67**   0.78        1.14        
  SK-MEL-28                    --                                                      --      --          --          --          --      --          **74.82**   --          --          
  SK-MEL-5                     --                                                      --      2.47        --          --          3.25    --          16.17       --          --          
  UACC-257                     --                                                      --      --          --          --          --      --          **74.83**   --          --          
  UACC-62                      --                                                      1.44    10.31       0.78        9.62        18.24   14.27       **86.54**   --          --          
                                                                                                                                                                                           
  Ovarian Cancer               IGROV1                                                  --      --          6.94        --          0.87    \_          --          **76.08**   --          5.25
  OVCAR-3                      --                                                      --      --          --          --          --      --          **65.08**   --          **91.83**   
  OVCAR-4                      --                                                      2.38    1.30        --          --          8.86    --          **80.50**   --          5.56        
  OVCAR-5                      5.33                                                    15.68   8.84        --          --          4.24    7.88        **52.48**   --          --          
  OVCAR-8                      --                                                      3.30    1.97        0.91        1.68        6.25    --          **85.94**   --          0.43        
  NCI/ADR-RES                  --                                                      7.90    21.95       --          --          --      5.66        **80.90**   --          --          
  SK-OV-3                      --                                                      --      --          --          --          24.57   7.19        **95.56**   --          --          
                                                                                                                                                                                           
  Renal Cancer                 786-0                                                   3.00    8.93        11.46       --          --      --          --          **91.01**   --          3.71
  A498                         18.12                                                   12.14   7.44        --          18.37       --      --          21.46       8.64        14.62       
  ACHN                         0.89                                                    6.27    5.86        --          0.28        13.55   7.13        **83.54**   --          --          
  CAKI-1                       --                                                      --      23.73       --          12.87       ---     29.75       **86.47**   4.83        24.71       
  RXF 393                      --                                                      --      --          --          --          2.16    2.27        **74.27**   --          --          
  SN12C                        --                                                      --      --          1.51        --          7.73    --          **76.94**   --          --          
  TK-10                        --                                                      5.94    5.32        **70.00**   --          16.23   5.88        **83.60**   2.97        6.83        
  UO-31                        --                                                      4.94    12.46       0.50        20.39       ---     13.47       **64.77**   9.87        27.79       
                                                                                                                                                                                           
  Prost.                       PC-3                                                    6.67    7.99        1.59        8.91        11.43   24.61       22.41       **58.41**   10.93       **61.01**
  Canc.                        DU-145                                                  --      --          --          --          --      --          --          **80.91**   --          31.32
                                                                                                                                                                                           
  Breast Cancer                MCF7                                                    --      4.97        --          6.68        6.98    15.10       1.80        **91.72**   4.60        --
  MDA-MB-231/ATCC              --                                                      --      --          4.83        --          24.17   14.77       **67.43**   2.75        --          
  HS578T                       --                                                      --      --          --          --          --      --          19.00       0.98        0.81        
  BT-549                       --                                                      --      --          --          --          --      --          **63.98**   --          --          
  T-47D                        --                                                      --      12.42       3.82        6.98        23.74   2.13        **86.73**   --          --          
  MDA-MB-468                   --                                                      --      --          --          --          --      --          **47.74**   --          --          

###### 

Values detected from 5 dilutions for compound (**VIIa**) on 60 cell lines

  Cell line type               GI50 (μM)   TGI (μM)   LC50 (μM)   
  ---------------------------- ----------- ---------- ----------- -------
  Leukemia                     CCRF-CEM    0.326      ---         \>100
  HL-60(TB)                    0.522       48.6       \>100       
  K-562                        1.37        \>100      \>100       
  MOLT-4                       0.625       \>100      \>100       
  RPMI-8226                    0.760       \>100      \>100       
  SR                           0.663       53.4       \>100       
                                                                  
  Non-Small Cell Lung Cancer   A549/ATCC   2.22       17.8        95.7
  EKVX                         1.50        52.0       \>100       
  HOP-62                       0.559       24.0       \>100       
  HOP-92                       0.383       30.9       \>100       
  NCI-H226                     4.23        62.9       \>100       
  NCI-H23                      2.97        \>100      \>100       
  NCI-H322M                    0.335       22.0       \>100       
  NCI-H460                     0.398       3.61       45.0        
  NCI-H 522                    1.79        \>100      \>100       
                                                                  
  CNS Cancer                   SF-268      0.646      23.0        \>100
  SF-295                       1.67        20.0       \>100       
  SF-539                       0.522       8.84       96.9        
  SNB-19                       1.55        64.6       \>100       
  SNB-75                       8.66        53.0       \>100       
  U251                         0.595       16.9       95.1        
                                                                  
  Melanoma                     LOX IMVI    0.389      11.9        57.1
  MALME-3M                     1.19        9.56       \>100       
  M14                          0.726       2.68       8.83        
  MDAMB435                     1.25        \>100      \>100       
  SK-MEL-2                     2.97        19.0       \>100       
  SK-MEL-28                    3.70        \>100      \>100       
  SK-MEL-5                     1.06        2.55       6.11        
  UACC-257                     3.49        24.7       \>100       
  UACC-62                      1.75        7.78       \>100       
                                                                  
  Ovarian Cancer               IGROV1      0.546      10.7        \>100
  OVCAR-3                      0.427       23.5       97.1        
  OVCAR-4                      0.578       73.4       \>100       
  OVCAR-5                      3.66        \>100      \>100       
  OVCAR-8                      0.477       36.1       \>100       
  NCI/ADR-RES                  0.419       22.6       \>100       
  SK-OV-3                      0.601       37.4       \>100       
                                                                  
  Renal Cancer                 786-0       1.58       15.8        \>100
  A498                         17.0        68.3       \>100       
  ACHN                         0.350       10.8       92.9        
  CAKI-1                       0.360       10.5       \>100       
  RXF 393                      4.31        30.7       \>100       
  SN12C                        0.983       84.0       \>100       
  TK-10                        2.60        46.9       \>100       
  UO-31                        0.348       3.51       \>100       
                                                                  
  Prostate                     PC-3        1.36       92.3        \>100
  Cancer                       DU-145      0.601      16.7        \>100
                                                                  
  Breast Cancer                MCF7        1.56       \>100       \>100
  MDA-MB-231/ATCC              0.719       42.7       \>100       
  HS578T                       7.34        77.6       \>100       
  BT-549                       3.05        78.3       \>100       
  T-47D                        2.58        \>100      \>100       
  MDA-MB-468                   2.15        7.81       \>100       
                                                                  
  Colon Cancer                 COLO 205    1.27       \>100       \>100
  HCC-2998                     0.656       \>100      \>100       
  HCT-116                      0.373       24.9       \>100       
  HCT-15                       0.409       \>100      \>100       
  HT29                         2.94        \>100      \>100       
  KM12                         0.686       \>100      \>100       
  SW-620                       2.31        \>100      \>100       
